- Home
- DLHC vs OTLK Comparison
DLHC vs OTLK Comparison
Compare DLHC & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLHC | OTLK |
|---|---|---|
| Founded | 1969 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 96.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | DLHC | OTLK |
|---|---|---|
| Price | $5.55 | $2.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 29.9K | ★ 2.7M |
| Earning Date | 02-04-2026 | 12-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $344,497,000.00 | $1,505,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $342.80 |
| P/E Ratio | $62.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.72 | $0.79 |
| 52 Week High | $8.45 | $3.39 |
Technical Indicators
Market Signals| Indicator | DLHC | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 54.43 |
| Support Level | $5.50 | $1.91 |
| Resistance Level | $5.65 | $2.54 |
| Average True Range (ATR) | 0.18 | 0.20 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 6.17 | 36.19 |
Price Performance
Historical ComparisonAbout DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.